


Cite this: *Nanoscale*, 2020, **12**, 10347

Local release of siRNA using polyplex-loaded thermosensitive hydrogels†

Lies A. L. Fliervoet,^a Heyang Zhang,^b Emma van Groesen,^c Kyra Fortuin,^a
 Naut J. C. B. Duin,^a Katrien Remaut,^b Raymond M. Schiffelers,^d
 Wim E. Hennink^a and Tina Vermonden^a*

One of the challenges for the clinical translation of RNA interference (RNAi)-based therapies concerns the deposition of therapeutically effective doses of the nucleic acids, like siRNA, at a local tissue level without severe off-target effects. To address this issue, hydrogels can be used as matrices for the local and sustained release of the siRNA cargo. In this study, the formation of polyplexes based on siRNA and poly(2-dimethylaminoethyl methacrylate) (PDMAEMA)-based polymers was investigated, followed by their loading in a thermosensitive hydrogel to promote local siRNA release. A multifunctional NPD triblock copolymer consisting of a thermosensitive poly(*N*-isopropylacrylamide) (PNIPAM, N), a hydrophilic poly(ethylene glycol) (PEG, P), and a cationic PDMAEMA (D) block was used to study the binding properties with siRNA taking the non-thermosensitive PD polymer as control. For both polymers, small polyplexes with sizes ranging from 10–20 nm were formed in aqueous solution (HBS buffer, 20 mM HEPES, 150 mM NaCl, pH 7.4) when prepared at a N/P charge ratio of 5 or higher. Formulating the siRNA into NPD or PD polyplexes before loading into the thermosensitive PNIPAM–PEG–PNIPAM hydrogel resulted in a more controlled and sustained release compared to free siRNA release from the hydrogel. The polyplexes were released for 128 hours in HBS, when changing the release medium twice a day, while free siRNA was completely released within 50 hours with already 40% being released after changing the release medium just once. The release of the polyplexes was dependent on the dissolution rate of the hydrogel matrix. Moreover, intact polyplexes were released from the hydrogels with a similar size as before loading, suggesting that the hydrogel material did not compromise the polyplex stability. Finally, it was shown that the released polyplexes were still biologically active and transfected FaDu cells, which was observed by siRNA-induced luciferase silencing *in vitro*. This study shows the development of an injectable thermosensitive hydrogel to promote local and sustained release of siRNA, which can potentially be used to deliver siRNA for various applications, such as the treatment of tumors.

Received 21st April 2020,
 Accepted 28th April 2020

DOI: 10.1039/d0nr03147j

rsc.li/nanoscale

1. Introduction

Since the discovery of RNA interference (RNAi) by Fire and Mello in 1998,¹ many researchers have focused on using this for therapeutic purposes. RNAi is a biological process in which RNA molecules, like microRNA (miRNA) and small interfering

RNA (siRNA), inhibit gene expression by binding to complementary messenger RNA (mRNA) resulting in silencing of the protein expression. The process is exploited to knock down specific genes creating many opportunities for treating diseases. Despite the high potential of these nucleic acid therapeutics, translation has been limited and only recently the first siRNA therapy was approved by the FDA.^{2,3} Efficient delivery of siRNA molecules in the target cells remains the major challenge for clinical translation. Nucleic acids are highly negatively charged and large hydrophilic molecules, making them unable to pass cellular membranes by passive diffusion. Moreover, siRNAs have a half-life of only a few minutes after intravenous administration due to their susceptibility to degradation by nucleases in the bloodstream and rapid renal clearance.⁴ Other challenges include induction of immune responses and off-target effects.⁵ To facilitate the intracellular delivery of siRNA, non-viral polymer-based systems have been


^aDepartment of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Faculty of Science, Utrecht University, PO Box 80082, 3508 TB Utrecht, the Netherlands. E-mail: T.Vermonden@uu.nl; Tel: (+31)620291631

^bLaboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Ghent 9000, Belgium

^cBiological Chemistry Group, Institute of Biology Leiden, Leiden University, Sylvius Laboratories, 2333 BE Leiden, the Netherlands

^dDepartment of Clinical Chemistry and Haematology, University Medical Center Utrecht, Heidelberglaan 100, 3508 GA Utrecht, the Netherlands

†Electronic supplementary information (ESI) available. See DOI: 10.1039/d0nr03147j



widely studied both *in vitro* and *in vivo*.^{6–8} Cationic polymers form complexes (*i.e.* polyplexes) with the negatively charged siRNA molecules exploiting electrostatic interactions, and these polyplexes protect siRNA from degradation and promote cellular uptake. A great variety of cationic polymers have been developed as nucleic acid carriers, including polyethylenimine (PEI), poly-L-lysine (PLL), polyamidoamine (PAMAM), and poly (2-dimethylaminoethyl methacrylate) (PDMAEMA).^{9–11} The advantages of these polymeric deliver systems are their tailorable design, the relatively ease to scale-up the production, and they are safer as compared to viral vectors. However, one of the challenges that remains is the accumulation of therapeutically effective doses of siRNA at a local tissue level with acceptable off-target effects.^{12,13} To address these limitations, hydrogels can be used to facilitate local and sustained release of siRNA. Hydrogels are water-swollen cross-linked networks of hydrophilic polymers, which have been used for the delivery of various biomolecules, including siRNA.^{14–17} The nucleic acids are entrapped within the hydrogel either as siRNA conjugates or loaded in nanoparticles, and the release kinetics can be tuned by varying hydrogel properties such as polymer concentration and cross-link density.^{17,18} In this way, hydrogels assist in local retention and sustained release of siRNA to enhance *in vivo* efficacy and at the same time limit off-target toxicity.¹⁸

While many hydrogels have been investigated for local release of therapeutics, injectable formulations are preferred over preformed hydrogels, since *in situ* gelation can take place under physiological conditions upon injection without the need of an invasive surgical intervention.^{19–21} Especially the use of stimuli-responsive polymers gained a lot of interest, as they can respond to external environmental triggers, like temperature, pH or light exposure.¹⁷ Temperature-sensitive hydrogels are one of the most studied class of stimuli-responsive polymer systems, and the self-assembly of these polymers occurs at a critical temperature, the so-called cloud point (CP) in aqueous solution. Because poly(*N*-isopropylacrylamide) (PNIPAM)-based polymers have a CP around 32 °C, they are very attractive materials for biomedical and pharmaceutical applications.^{22,23}

Previously, a multifunctional triblock copolymer consisting of a thermosensitive PNIPAM, an hydrophilic poly(ethylene glycol) (PEG) and a cationic PDMAEMA block was investigated for the release of plasmid DNA (pDNA). The presented results showed that multiple functionalities can be introduced in the polymer design without compromising the interactions with pDNA and hence the polyplex structure.²⁴ The aim of the present study is to investigate the applicability of the thermosensitive polyplexes based on the NPD (N = PNIPAM, P = PEG, D = PDMAEMA) triblock copolymer for siRNA delivery. Furthermore, the loading of these polyplexes into a thermosensitive PNIPAM-PEG-PNIPAM hydrogel was evaluated to facilitate local and sustained release of siRNA. First, the physical-chemical properties of polyplexes formed between siRNA and the multifunctional NPD polymer were evaluated taking a non-thermosensitive polymer as control. Second, the release profile of polyplexes from the thermosensitive PNIPAM-PEG-PNIPAM

hydrogel was evaluated as well as the ability of the released polyplexes to deliver siRNA *in vitro* into cells.

2. Materials and methods

2.1. Materials

All materials were obtained from Sigma-Aldrich (Zwijndrecht, the Netherlands) and used as received unless noted otherwise. Acetonitrile (ACN) and *N,N*-dimethylformamide (DMF) were purchased from Biosolve (Valkenswaard, the Netherlands) and DMF was dried by molecular sieves for 24 hours before use. To remove the inhibitor from 2-(dimethylamino)ethyl methacrylate (DMAEMA), the monomer was passed over a column of alumina prior to use. Slide-A-lyzer™ Dialysis cassettes (Molecular weight cut-off, MWCO: 10 kDa) were obtained from Thermo Fisher Scientific (Bleiswijk, the Netherlands). Agarose multi-purpose was purchased from Roche Molecular Biochemicals (Mannheim, Germany) and Midori Green DNA gel stain was obtained from Nippon Genetics (Düren, Germany). Human epithelial hypopharyngeal carcinoma cells stably expressing luciferase (FaDu-luc) were obtained from Erasmus Medical Center (Rotterdam, the Netherlands).²⁵ Linear polyethylenimine (l-PEI, Mw 25 kDa) was obtained from Polysciences (Hirschberg an der Bergstraße, Germany). Lipofectamine 3000, alamarBlue™ Cell Viability Reagent and Quant-iT™ RiboGreen™ RNA Assay Kit were purchased from Thermo Fisher Scientific and Luciferase assay kit was obtained from Promega (Leiden, the Netherlands).

The siRNA specifically targeting firefly luciferase and the negative control siRNA were provided by GlaxoSmithKline (Stevenage, UK) and their sequences are shown in Table 1. siRNA labeled with Alexa 647 was used for fluorescence correlation spectroscopy (FCS) experiments and this Alexa 647 labeled siRNA has the negative control sequence with the label present at the 3' end of the sense strand.

2.2. Synthesis and characterization of polymers

2.2.1. Synthesis of NPD triblock copolymers. The triblock copolymer consisting of PNIPAM-PEG-PDMAEMA (NPD) was synthesized following a two-step procedure using the hetero-functional PEG macroinitiator ((Br-C(CH₃)₂-CO-NH-PEG₅₀₀₀)₂-ABCPA) as previously reported.²⁶ The first step involved atom transfer radical polymerization of NIPAM. For this, the PEG macroinitiator (1 equiv.), NIPAM (283 equiv.) and

Table 1 Overview of siRNA sequences used

| siRNA | Sequence |
|-----------------------------------|--|
| Luciferase siRNA (siRNA-luc) | Sense 5'- <u>CUU</u> - <u>ACG</u> - <u>CUG</u> -AGU-ACU-UCG-AdTdT-3' Antisense 5'- UCG-AAG-UAC-UCA-GCG-UAA-GdTdT-3' |
| Negative control siRNA (siRNA-nc) | Sense 5'-AUC-GUA-CGU-ACC-GUC-GUA-UdTdT-3' Antisense 5'- <u>AUA</u> - <u>CGA</u> - <u>CGG</u> - <u>UAC</u> - <u>GUA</u> - <u>CGA</u> -UdTdT-3' |

Underlined bases indicate a 2'-O-methyl modification. dT indicates a deoxyribonucleic acid base having phosphorothioate (PS) bond.



CuBr (8 equiv.) were dissolved in 3.5 mL water in an airtight screw-cap glass vial with a final NIPAM concentration of 90 mg mL⁻¹. The reaction mixture was flushed with nitrogen for 15 min at room temperature (RT) and subsequently another 15 min on ice. Next, 18 equiv. of tris[2-(dimethylamino)ethyl] amine (Me₆TREN) as catalyst was added and the polymerization reaction was carried out for three hours on ice. Subsequently, the polymer solution was transferred into a dialysis cassette (MWCO: 10 kDa) and dialyzed against water for 48 hours at 4 °C, while changing the dialysate three times a day. The resulting NPPN polymer was recovered by freeze drying. The second step of the polymerization route involved the synthesis of the PDMAEMA block by free radical polymerization. The NPPN polymer (1 equiv.) and DMAEMA (790 equiv.) were dissolved in dry DMF in an airtight Schlenk flask with a final DMAEMA concentration of 300 mg mL⁻¹. Freeze-pump-thaw cycles were applied to degas the solution, and afterwards vial with the reaction mixture was placed in an oil bath at 70 °C and stirred for 24 hours under N₂ atmosphere. Next, the polymer solution was dialyzed (MWCO: 10 kDa) against water for 48 hours at 4 °C, while changing the dialysate three times a day, and subsequently freeze dried to obtain the final NPD polymer. As a control, a non-thermosensitive polymer lacking the PNIPAM block was synthesized. For this, a PEG macroinitiator without ATRP initiator (Boc-NH-PEG₅₀₀₀)₂-ABCPA (1 equiv.) together with DMAEMA (800 equiv.) were dissolved in dry DMF and the same procedure as described above was applied resulting in the corresponding PD diblock polymer.

2.2.2. Synthesis of NPN triblock copolymers. The triblock copolymer consisting of PNIPAM-PEG-PNIPAM (NPN) was synthesized following a previously reported procedure using the PEG macroinitiator ((Br-C(CH₃)₂-COO)₂-PEG₆₀₀₀).²⁷ In brief, the PEG macroinitiator (1 equiv.), NIPAM (302 equiv.), CuBr (1 equiv.) and CuBr₂ (1 equiv.) were placed in an airtight screw-cap glass vial and 12 mL of H₂O/ACN (4 : 1) mixture was added. The reaction mixture was flushed with nitrogen and placed in an ice bath while stirring until all compounds were completely dissolved. Subsequently, 2 equiv. of Me₆TREN was added and the polymerization reaction was carried out for one hour on ice. The polymer solution was dialyzed (MWCO: 10 kDa) against water for 48 hours at 4 °C, while changing the dialysate three times a day and subsequently lyophilized.

2.2.3. Characterization of polymers. The synthesized polymers were characterized with ¹H-NMR spectroscopy using an Agilent 400 MR-NMR spectrometer (Agilent Technologies, Santa Clara, CA, USA). Chemical shifts are referred to the residual solvent peak (δ = 7.26 ppm for CDCl₃ and δ = 4.80 ppm for D₂O) and data analysis was performed using MestReNova Software version 10.0.1-14719. The obtained polymers were also characterized by GPC using a Waters Alliance System (Waters Corporation, Milford, MA, USA) equipped with a refractive index (RI) detector and a PLgel 5 μ m MIXED-D column (Polymer Laboratories) using DMF containing 10 mM LiCl as eluent.²⁸ The flow rate was 1.0 mL min⁻¹ and 50 μ L of polymer solution (3 mg mL⁻¹) was injected into the column. The column temperature was 65 °C and calibration was per-

formed using PEG standards of narrow and defined molecular weights (PSS GmbH, Mainz, Germany). Data analysis was performed using Empower 3 Software 2010. The cloud point (CP) of the synthesized thermosensitive polymers was determined by light scattering using a Jasco FP-8300 spectrophotometer (JASCO, Easton, MD). Samples of the polymers were prepared at a concentration of 2 mg mL⁻¹ in 20 mM *N*-(2-hydroxyethyl) piperazine-*N'*-(2-ethanesulfonic acid) (HEPES) buffer, pH 7.4. The scattering intensity of the polymer solution was measured at 550 nm while increasing the temperature from 10 to 60 °C with a heating rate of 1 °C min⁻¹. The onset of increased scattering intensity was taken as the cloud point.²⁹

2.3. Polyplex preparation

Polymer stock solutions (ranging from 110–1370 μ g mL⁻¹, depending on polymer type and intended N/P ratio), and siRNA stock solution (30 μ M) were prepared in HBS buffer (20 mM HEPES, 150 mM NaCl, pH 7.4) and cooled at 0 °C. Next, the polymer solution was added to the siRNA solution in a 2 : 1 volume ratio (typically 400 : 200 μ L), and the mixture was vortexed for 10 seconds. The formed polyplexes were incubated at 0 °C for 30 minutes before further use.

2.4. Polyplex characterization

2.4.1. Dynamic light scattering (DLS) and laser Doppler electrophoresis (LDE) analysis of polyplexes. DLS was used to determine the hydrodynamic size and polydispersity index (PDI) of the formed polyplexes. Samples were prepared as described in section 2.3 at a final siRNA concentration of 10 μ M in HBS buffer (20 mM HEPES, 150 mM NaCl, pH 7.4). The measurements were performed on a Zetasizer Nano S (Malvern Instruments, Malvern, UK) with an He-Ne laser operating at 633 nm, and temperature controller set at 10 and 37 °C. Data were corrected for viscosity using the Malvern Zetasizer software (version 7.12). The ζ -potential of the polyplexes was measured using laser Doppler electrophoresis on a Zetasizer Nano Z (Malvern Instruments). For this, samples were prepared in HEPES buffer (20 mM HEPES, pH 7.4) with a siRNA concentration of 10 μ M.

2.4.2. Agarose gel retardation assay. Polyplex dispersions were prepared as described in section 2.3 and diluted with HBS to a final siRNA concentration of 1 μ M. To assess the stability in the presence of serum, the polyplexes dispersed in 10% fetal bovine serum (FBS) were incubated for 2, 4, and 6 hours at 37 °C. Next, 10 μ L of the polyplex sample was mixed with 2 μ L heparin sodium salt solution (20 mg mL⁻¹) or 2 μ L HBS buffer and incubated for 1 hour at room temperature. Afterwards, 2 μ L of 6 \times loading dye was added to the mixture and loaded into a 1.5% agarose gel containing Midori Green in a tris-acetate-EDTA (TAE) buffer. The gel was run at 35 V for 40 minutes and analyzed by a ChemiDoc™ Imager (Bio-Rad Laboratories Inc., Hercules, CA) using Image Lab software (version 6.0.1).

2.4.3. Fluorescence correlation spectroscopy (FCS). The size of fluorescently labeled siRNA polyplexes was investigated by FCS measurements as previously described.³⁰ Fluorescently



labeled particles continuously move in and out of the detection volume (*i.e.* confocal volume), causing fluctuations in the fluorescence signal. From these fluctuations, an auto-correlation curve can be derived that subsequently gives information about the diffusion coefficient of the fluorescent particles present in the detection volume.^{31,32} Polyplexes containing Alexa 647 labeled siRNA were prepared as described in section 2.3 and subsequently diluted with HBS buffer to a final siRNA concentration of 150 nM. To assess the stability, the polyplexes were incubated for 6 hours at 37 °C with or without 10% FBS. Afterwards, 40 µL of each sample was transferred onto a coverslip (µ-slide Ibidi, Gräfelfing, Germany). The coverslip was placed in a temperature controlled plate to maintain the temperature of the sample at 37 °C. FCS measurements were performed using a confocal microscope (Nikon C1, Japan) equipped with a 640 nm laser and a water immersion objective lens (60× Plan Apo VC, N.A. 1.2, Nikon). For each sample, the fluctuations of fluorescence intensity were recorded by a photon counting instrument (PicoHarp 300, PicoQuant, Berlin, Germany) for 60 seconds in triplicate. The obtained time traces were analyzed using SymPhoTime (PicoQuant) and data were fitted using the triple-state model to obtain diffusion coefficients and concentration of fluorescent particles or molecules. The size was determined using the Stokes–Einstein equation.

$$D = \frac{k_B T}{6\pi\eta R_H} \quad (1)$$

In which D is the diffusion coefficient, k_B the Boltzmann's constant, T the absolute temperature, η the viscosity, and R_H the hydrodynamic radius of the particle.

2.5. Hydrogel formation and polyplex/siRNA release

The NPN polymers (final concentration of 15% w/w) were dissolved in the NPD or PD polyplexes dispersions (N/P 5 mol/mol, final siRNA concentration of 500 µM) overnight at 4 °C. Free siRNA (thus not formulated as polyplexes; same final concentration) was included as a control. Next, the glass vials were placed at 37 °C and gels (100 µL) were allowed to form. After 30 minutes, 500 µL of prewarmed release buffer (HBS, 20 mM HEPES, 150 mM NaCl, pH 7.4) of 37 °C was added on top of the hydrogels. Twice a day, 450 µL of the release medium was replaced with fresh prewarmed release buffer and the concentration of siRNA in the samples was determined using the RiboGreen Assay (section 2.6).

2.6. Quantification of siRNA with Quant-iT™ RiboGreen™ assay

The amount of siRNA released from the thermosensitive hydrogel was quantified using an intercalating reagent that produces a fluorescent signal. First, release samples were diluted 100 times and 40 µL was transferred into a 96-well plate. Next, 55 µL of heparin solution (4.5 mg mL⁻¹) was added to the release samples and incubated for 1 hour at RT to destabilize the polyplexes. Next, the commercially available Quant-iT™ RiboGreen® RNA Assay Kit was used according

to the manufacturer's protocol and the 'high range assay' (20 ng mL⁻¹ to 1 µg mL⁻¹) was selected. The siRNA's with the same sequences were used for calibration and the fluorescence signal was measured at 484/520 nm using a Jasco FP-8300 spectrophotometer (JASCO, Easton, MD).

2.7. Characterization of released polyplexes by fluorescence correlation spectroscopy (FCS)

The size of the released polyplexes from the thermosensitive hydrogel was determined by FCS measurements. Polyplexes containing Alexa 647 labeled siRNA were prepared as described in section 2.3 and subsequently loaded in thermosensitive hydrogels as described in section 2.5. Release medium was refreshed twice a day and at predetermined timepoints (8 and 72 hours) 40 µL of the release medium was transferred onto a coverslip. In parallel, to destabilize the polyplexes, 90 µL of the release medium was mixed with 10 µL heparin sodium salt solution (20 mg mL⁻¹) and incubated for 1 hour at RT. Afterwards, 40 µL of each sample was transferred onto a coverslip. The coverslips were placed in a temperature controlled plate to maintain the temperature at 37 °C. FCS measurements were further performed as described in section 2.4.3.

2.8. *In vitro* transfection activity of polyplexes

In vitro studies were performed according to recommendations as previously described.³³ FaDu cells which stably express firefly luciferase were cultured in Dulbecco's Modified Eagle's Medium (DMEM) with high glucose (4.5 g L⁻¹ glucose) supplemented with 10% FBS (referred to as full medium) at 37 °C in a humidified atmosphere containing 5% CO₂. Transfection studies were done in 96-well plates, with FaDu-luc cells seeded at a density of 7000 cells per well 24 hours before transfections. At the day of the experiment, cells were washed once with PBS and incubated with 150 µL of various siRNA formulations (anti-luciferase or negative control) in complete medium for 6 hours at 37 °C. For the experiments with fresh polyplexes, particles were prepared on the same day as described in section 2.3 and subsequently diluted in full medium (100 or 500 nM siRNA). Commercially available transfection agents, l-PEI (25 kDa) and Lipofectamine 3000, were included as positive controls and complexes were prepared according to manufacturer's protocol. Free siRNA, without a transfection agent, was included as negative control. Cells treated with only medium were used as negative control and each condition was measured in octuple. For the released polyplexes, the supernatant from the hydrogels collected at various timepoints (8, 24, 48 and 72 hours) was diluted with full medium to yield a final siRNA concentration of 100 or 500 nM. Each condition was measured in quadruple. All transfection mixtures were replaced after 6 hours incubation by 200 µL fresh medium and the plates were incubated for another 24 hours at 37 °C. After 16 hours, medium was replaced with 100 µL fresh medium containing 1× alamarBlue (50 nM) and incubated for 4 hours at 37 °C to assess the cytotoxicity of the tested formulations. From each well, 80 µL was transferred into a new 96-well plate and the absorbance at 570 nm (taking



630 nm as a reference) was measured using a BMG SPECTROstar Nano wellplate reader (BMG Labtech, de Meern, the Netherlands). Medium containing 1× alamarBlue was included as blank. Data analysis was performed using MARS Data analysis software version 2.22 (BMG Labtech) and cell viability was calculated relative to untreated cells. To evaluate siRNA-induced silencing, a Luciferase Assay was performed. Medium was removed and the cells were lysed with 100 μ L lysis buffer (25 mM tris(hydroxymethyl)aminomethane (Tris), 2 mM dithiothreitol (DTT), 2 mM 1,2-diaminocyclohexane-*N,N,N',N'*-tetraacetic acid (DCTA), 1% Triton X-100, 10% glycerol) on a shaking board at RT for 15 minutes. Thereafter, 50 μ L of lysate was transferred into a white luminescence plate and 50 μ L of Luciferase Assay Reagent was injected using a FLUOstar OPTIMA microplate reader (BMG Labtech, Ortenberg, Germany) equipped with an injection pump. After two seconds, luminescence was measured for ten seconds according to supplier's recommendation.

3. Results and discussion

3.1. Polymer synthesis and characterization

The NPD triblock copolymer consisting of a PEG midblock (P), flanked by blocks of PNIPAM (N) and PDMAEMA (D) to introduce thermosensitive and cationic properties into the polymer structure, respectively, was synthesized and characterized (Fig. 1A and Table 2). The polymer synthesis followed a two-step synthesis route using a hetero-functional PEG macro-initiator as reported before (Scheme S1†).²⁶ In the first step, NIPAM was polymerized by ATRP and the corresponding NPPN polymer (N = PNIPAM, P = PEG) was obtained with a monomer conversion of 92% based on ¹H-NMR analysis and a yield of 90% (Table 2). Subsequently, classical free radical polymerization was used to polymerize DMAEMA to yield the final NPD triblock copolymer. DMAEMA conversion was 79% as determined with ¹H-NMR and the polymer was obtained in a yield of 71% (Table 2, Fig. S1†). A non-thermosensitive PD diblock




Fig. 1 (A) Chemical structure of NPD triblock polymer consisting of a 5 kDa PEG midblock (P), flanked by blocks of PNIPAM (N) and PDMAEMA (D). (B) Chemical structure of PD diblock polymer consisting of a 5 kDa PEG block (P) and a PDMAEMA (D) block. (C) Chemical structure of NPN triblock polymer consisting of a 6 kDa PEG block (P) flanked by blocks of PNIPAM (N).

Table 2 Characteristics of NPPN, NPD and PD block copolymers synthesized by radical polymerization using the hetero-functional PEG macro-initiator. The polymer names are abbreviated according to the block composition (N = PNIPAM, P = PEG, D = PDMAEMA)

| Name | Feed initiator : monomer ratio (mol/mol) | Monomer conversion ^a (%) | <i>M_n</i> N block ^a (kDa) | <i>M_n</i> P block ^a (kDa) | <i>M_n</i> D block ^a (kDa) | Total <i>M_n</i> ^a (kDa) | Total <i>M_n</i> ^b (kDa) | PDI ^b | Cloud point ^c (°C) |
|------|--|-------------------------------------|---|---|---|---|---|------------------|-------------------------------|
| NPPN | 1 : 283 | 92 | 29 | 10 (2 × 5) | n.a. | 39 | 64 | 1.6 | n.d. |
| NPD | 1 : 790 | 79 | 15 | 5 | 49 | 69 | 51 | 1.9 | 34 |
| PD | 1 : 800 | 77 | n.a. | 5 | 47 | 52 | 32 | 2.1 | n.d. |
| NPN | 1 : 302 | 100 | 34 | 6 | n.a. | 40 | 45 | 1.2 | 35 |

^a Determined by ¹H-NMR. ^b Determined by GPC. ^c Determined by light scattering at 550 nm. n.d. = not determined, n.a. = not applicable.



copolymer lacking the PNIPAM block was also synthesized (Fig. 1B) and a similar monomer conversion of DMAEMA (77%) and polymer yield (68%) were obtained as for the NPD polymer (Table 2, Fig. S2†). A NPN (N = PNIPAM, P = PEG) triblock copolymer (Fig. 1C) was synthesized according to a previously reported method²⁷ and its characteristics are summarized in Table 2. The monomer conversion based on ¹H-NMR analysis was 100% (Fig. S3†), and the obtained polymer had a rather narrow polydispersity index (PDI 1.2), which is expected for polymers synthesized by controlled radical polymerization. The cloud points of the synthesized polymers (NPD and NPN) were 34 and 35 °C, respectively (Table 2, Fig. S4†). The rheological properties of the temperature dependent gelation behavior of NPN, as well as representative images of the thermosensitive hydrogel before and after gelation are shown in the ESI (Fig. S5 and S6†). The injectability as previously shown by De Graaf *et al.*,²⁷ was confirmed by passing the solution through a 23 G needle.

3.2. Polyplex characterization

The thermosensitive NPD and the non-thermosensitive PD polymers (Table 2) were used to prepare siRNA-containing polyplexes at various N/P ratios. The N/P ratio is defined as the molar ratio between the amine groups (N) on the cationic polymers and the phosphate groups (P) on the siRNA. Increasing the N/P molar ratio from 1 to 5 resulted in a significant

decrease in NPD polyplex size from 108 ± 1 to 23 ± 1 nm (Fig. 2A). A further increase of the N/P ratio to 10 did not result in a further decrease in the size of the polyplexes. The same trend was observed for the PD polyplexes, for which a decrease in polyplex size from 158 ± 1 to 23 ± 1 nm (N/P 1 and 5, respectively) was found upon increasing N/P ratio (Fig. 2A). Interestingly, polyplexes prepared with N/P 1 had very narrow size distributions (PDI < 0.1), while PDIs of polyplexes with higher N/Ps increased but were still within an acceptable range (<0.3) (Fig. 2B). The polyplexes prepared at an N/P ratio of 1 had a ζ -potential of -3 ± 1 mV and -1 ± 1 mV (NPD and PD polyplexes, respectively) indicating incomplete shielding of the siRNA molecules (Fig. 2C). As expected, with an increasing N/P ratio of the formulation, due to the excess of cationic groups, the polyplexes showed an increase in ζ -potential (up to $+9 \pm 1$ mV at an N/P ratio of 10 for PD polyplexes). Slightly higher ζ -potentials were found for PD polyplexes as compared to NPD polyplexes ($+9 \pm 1$ mV and 5 ± 1 mV at N/P 10, respectively), which can be explained by the additional shielding of the hydrophilic PNIPAM block (below the CP) in the NPD polyplexes. Similar findings were also reported before for polyplexes containing pDNA.²⁴ The ability of the cationic polymers to complex with siRNA was evaluated by an agarose gel retardation assay. Even at low N/P ratios, no free siRNA was detected in the both types of polyplex dispersions, indicating that all siRNA molecules complexed with the cationic polymers




Fig. 2 Characteristics of NPD and PD polyplexes prepared at different N/P ratios. (A & B) Particle size and polydispersity index (PDI) of the polyplexes containing non-coding siRNA (siRNA-nc) as determined by dynamic light scattering (DLS) in HBS buffer (20 mM HEPES, 150 mM NaCl, pH 7.4). All polyplexes were formed at 0 °C, and were subjected to a temperature change from 10 to 37 and back to 10 °C. An NPD polymer solution (no siRNA added) was included as control for micelle formation at 37 °C. (C) ζ -Potential of polyplexes measured at 10 and 37 °C by laser Doppler electrophoresis (LDE) in HEPES buffer (20 mM HEPES, pH 7.4). All values are given as the mean \pm SD ($n = 3$). (D) Agarose gel retardation assay of NPD and PD polyplexes in HBS buffer (left). In parallel, heparin was added to destabilize the polyplexes and release siRNA from the cationic polymers (right).



(Fig. 2D). To show the reversibility of the electrostatic interactions, strongly negatively charged heparin was added to the polyplexes, which resulted in release of siRNA (Fig. 2D).

3.3. Polyplex stability at 37 °C

Since the NPD polyplexes contain thermosensitive blocks, the effect of temperature changes above (37 °C) and below (10 °C) the CP was evaluated by DLS. For polyplexes prepared at N/P 1 and 3, increasing the temperature to 37 °C resulted in polyplexes with larger sizes (298 ± 3 at 37 °C and 362 ± 12 at 37 °C, respectively) and broader size distributions (Fig. 2A and B). A similar effect was observed for PD polyplexes with the same N/P ratio, suggesting that the observed changes for NPD polyplexes with temperature are not caused by the thermosensitive PNIPAM block. Additionally, the increase in size at 37 °C was not completely reversible after cooling down the polyplexes again to 10 °C (Fig. 2A). The size of NPD polyplexes at N/P1 increased from 108 ± 1 to 298 ± 3 nm upon heating from 10 to 37 °C, whereas upon cooling to 10 °C the size was 304 ± 6 nm. Fig. 2A also shows that for the NPD polyplexes prepared at N/P 5 and 10, a significant increase in particle size (from ~ 23 nm to ~ 170 nm) was observed when heated to 37 °C, which was

completely reversible after cooling down to 10 °C. The particle size of PD polyplexes with N/P 5 and 10 remained unchanged during the same temperature changes. At N/P 5 and 10, a large excess of polymer is added to the siRNA, making it likely that free polymer chains are present in the polyplex dispersion. In addition, the free polymer chains can self-assemble into micellar structures at 37 °C, because of the presence of the thermosensitive PNIPAM blocks. Indeed, the control sample containing only NPD polymer, showed the presence of particles with a similar size (~ 165 nm) at 37 °C (Fig. 2A). In addition, the ζ -potential of NPD polyplexes slightly increased at 37 °C which can indicate the presence of positively charged micellar structures (Fig. 2C). The stability of the polyplexes was studied in HBS buffer (20 mM HEPES, 150 mM NaCl, pH 7.4) over time. DLS measurements showed that the size of PD polyplexes (N/P 5) remained constant (~ 30 nm) after incubation for 16 hours at 37 °C (Fig. 3B). Again, at 37 °C the size of the NPD polyplexes (N/P 5) significantly increased in time (from 25 to 120 nm), which was similar to the micelle size formed by the NPD polymer alone (Fig. 3A and C). Cooling down the polyplexes to 10 °C after 16 hours incubation at 37 °C, resulted again in only the small sized polyplexes (23 nm). Polyplexes




Fig. 3 Size of NPD and PD polyplexes (N/P 5) containing siRNA at 37 °C as determined by dynamic light scattering (DLS) in HBS buffer (20 mM HEPES, 150 mM NaCl, pH 7.4) (A & B). NPD polymer solution (no siRNA added) was included as control for micelle formation at 37 °C (C). After 16 hours, the formulations were cooled down to 10 °C and measured again.



prepared at N/P ratios of 1 and 3 showed significant increase in size and PDI over time (Fig. S7†). From literature it is known that among others particle size is a very important factor for the uptake efficiency of complexes. For example, it has been shown that the uptake efficiency of 20 and 40 nm nanoparticles was 5–10 times greater than that of 100 nm particles.³⁴ Not only the efficiency of the uptake but also the type of uptake pathway by which the particles are internalized, is influenced by the size of the particles.³⁵

Fluorescence correlation spectroscopy (FCS), a light microscopy based technique used to study interactions on the single molecule level, was exploited to further characterize the thermosensitive polyplexes at 37 °C. FCS showed that free siRNA in buffer and at 37 °C has a diffusion coefficient of $181 \pm 7 \mu\text{m}^2 \text{s}^{-1}$ (Fig. 4A) which using the Stokes–Einstein equation corresponds to a size of 2 nm, that is in line with earlier reported sizes for siRNA molecules (Fig. 4B).^{36,37} FCS measurements showed that the diffusion coefficient for both NPD and PD polyplexes prepared at N/P ratio of 1 and 3 was $\sim 3 \mu\text{m}^2 \text{s}^{-1}$, which corresponds to a particle size of ~ 100 nm (Fig. 4A and B). On the other hand, the diffusion coefficients of polyplexes prepared at higher N/P ratios 5 and 10 were around 10 times larger ($\sim 30 \mu\text{m}^2 \text{s}^{-1}$) for both types of polymers. This diffusion coefficient corresponds to a polyplex size of ~ 10 nm, which is in the same range as the small particle size found by DLS at 10 °C (Fig. 2A and Fig. 4B). These results confirm the presence of micellar structures in the NPD polyplex dispersions, which dominate the DLS measurement of NPD polyplexes (N/P 5 and 10) at 37 °C. Particles in a colloid dispersion scatter an incident laser beam, and the intensity of this scattered light is proportional to the 6th power of the diameter of the particles.³⁸ As a consequence, the excessive scattering of bigger particles can mask the low intensity scattering from smaller particles.³⁹

Polyplexes with comparable small sizes (10–30 nm) have been reported in literature before using various block copolymers.^{40–45} For example, Hayashi *et al.* used poly(ethylene glycol)-*b*-poly(L-lysine) (PEG–PLL) block copolymers to complex siRNA and reported sizes of around 10 nm for polyplexes based on this block copolymer.⁴² The authors attribute this small size to a monomolecular assembly of the positively charged polymer chain and the negatively charged siRNA molecule. In other words, it is considered that each particle consists of a single siRNA molecule complexed with one PEG–PLL chain *via* electrostatic interactions. In the present study, it is shown that the polyplex size is dependent on the N/P ratio, where the small polyplexes are only observed at higher N/P ratios (N/P ≥ 5). At higher N/P ratios, the siRNA molecules become more diluted over the polymer chains making it possible that at some point the self-assembly behavior resembles that of PEG–PLL, in which each polyplex contains a single siRNA molecule. From the FCS data, an estimation of the number of siRNA molecules per complex can be calculated by normalizing the fluorescent particle concentration of the polyplexes to that of free siRNA,⁴⁶ assuming that no quenching occurs. If quenching would occur to a large extent, the peaks in the FCS time traces are likely to disappear,⁴⁷ which was not observed (Fig. S8A, C, E and G†). It is determined that indeed polyplexes prepared at N/P 5 and 10 contain between 1–3 siRNA molecules per complex compared to >100 siRNAs for polyplexes at N/P 1 and 3 (Table 3).

Polyplexes prepared with both types of polymers at different N/P ratios were incubated with or without fetal bovine serum (FBS). A significant increase in polyplex size (from 149 ± 9 to 866 ± 204 nm) was observed for NPD polyplexes with N/P 1 when incubated without FBS for 6 hours at 37 °C, which is in line with the DLS results (Fig. 2A and 4B). In contrast, the




Fig. 4 Characteristics of NPD and PD polyplexes prepared at different N/P ratios in HBS buffer (20 mM HEPES, 150 mM NaCl, pH 7.4) as determined by fluorescence correlation spectroscopy (FCS). Diffusion coefficient (A) and size (B) of Alexa 647 siRNA in freshly prepared polyplexes was compared with Alexa 647 siRNA in polyplexes incubated for 6 hours at 37 °C with or without FBS. Free Alexa 647 siRNA was included as control. Measurements were performed at 37 °C. Mean \pm SD ($n = 3$).



Table 3 Polyplex size and estimation of number of siRNA molecules per complex as determined by fluorescence correlation spectroscopy (FCS). The polymer names are abbreviated according to the block composition (N = PNIPAM, P = PEG, D = PDMAEMA). Mean \pm SD ($n = 3$)

| Polymer | N/P ratio | Polyplex size (nm) | Number of siRNA molecules per complex |
|---------|-----------|--------------------|---------------------------------------|
| NPD | 1 | 149 \pm 9 | 102 \pm 2 |
| | 3 | 88 \pm 13 | 128 \pm 9 |
| | 5 | 10 \pm 1 | 3 \pm 1 |
| | 10 | 12 \pm 1 | 2 \pm 1 |
| PD | 1 | 100 \pm 16 | 132 \pm 32 |
| | 3 | 137 \pm 22 | 109 \pm 5 |
| | 5 | 12 \pm 1 | 2 \pm 1 |
| | 10 | 12 \pm 1 | 1 \pm 1 |

observed sizes of the polyplexes at N/P 1 and 3 did not change after incubation with FBS at 37 °C. However, the FCS time traces showed a significant decrease in the count rate (Fig. S8†), which might indicate aggregation and subsequent sedimentation of the particles. Interestingly, FCS analysis showed that the size of NPD and PD polyplexes prepared at higher N/P ratios of 5 and 10 did not change significantly when incubated at 37 °C for 6 hours without FBS (Fig. 4B). However, in the presence of serum, the originally small sized NPD polyplexes (size \sim 10 nm; N/P 5 and 10) aggregate to bigger particles of around 200 nm after 6 hours incubation (Fig. 4B). It should be noted that such a polyplex size is still generally considered acceptable to achieve efficient transfection.^{11,48} The same trend was observed for the PD polyplexes (N/P 5 and 10) which increased slightly more in size to around 400 nm after incubation with FBS for 6 hours at 37 °C. To evaluate whether siRNA loaded in NPD polyplexes is protected against degradation by RNases present in FBS, an agarose retardation assay was performed (Fig. S9†). Compared to the observed band for free siRNA in buffer (shown at N/P 0), a time-dependent decrease in intensity was clearly seen when siRNA was incubated with serum, indicating the presence of nucleases in FBS. When the siRNA was complexed with polymers, only the polyplexes with N/P 1 showed a significant decrease in siRNA signal in the gel, while all other formulations obviously protected the loaded siRNA against degradation.

3.4. Hydrogel formation and siRNA release

Polyplexes prepared at N/P 5 were selected for further studies because of their small size and excellent colloidal stability in buffer and good stability in serum. These polyplexes were loaded in a thermosensitive hydrogel based on the PNIPAM-PEG-PNIPAM (NPN) triblock polymer by mixing NPD or PD polyplexes (N/P 5) with a NPN solution at 4 °C and subsequently increasing the temperature to 37 °C enabling gel formation. Free siRNA was quantitatively released from the hydrogels in 50 hours (Fig. 5, circles). Moreover, a rapid release was observed for this formulation, since 40% of the siRNA was released after changing the release medium just once. When siRNA was embedded in the hydrogel as polyplexes, a signifi-




Fig. 5 Release of luciferase siRNA (siRNA-luc) from a thermosensitive hydrogel in its free form, or formulated as NPD or PD polyplexes (N/P 5) at 37 °C. The values are given as the mean \pm SD ($n = 3$).

cant slower and more controlled release was observed. For both type of polyplexes (NPD and PD polyplexes), siRNA was quantitatively released during 128 hours (Fig. 5, squares and triangles). Furthermore, the amount of siRNA released was rather similar per time point, which suggests that the release of the polyplexes is dependent on the dissolution rate of the hydrogel system. This is not completely surprising, since the hydrogel is physically cross-linked and it has been reported before that the equilibrium between the hydrogel and free polymer chains in solution influences the dissolution rate of such systems.^{27,49} The NPN triblock copolymers are known to form micelles in aqueous solutions above their CP, and at high concentrations the micelles are closely packed into a hydrogel hold together by “bridging” chains. When this hydrogel is immersed into an aqueous medium, an equilibrium between bridged micelles in the gel, free micelles and unimers in solution is established.^{27,50} As a result, the frequency with which the medium is refreshed determines the dissolution rate of the hydrogel, and consequently the release of the entrapped polyplexes. As a consequence, the release profiles *in vivo* may be substantially different from the ones observed *in vitro* studies because of a more dynamic environment *in vivo*. The rationale for comparing the thermosensitive NPD polyplexes with the non-thermosensitive PD polyplexes was based on the hypothesis that, in the case of the NPD polyplexes, besides dissolution of the hydrogel also interactions between the PNIPAM blocks in the polyplexes and those present in the hydrogel may play a role in the kinetics of polyplex release. However, no significant differences in release kinetics between the NPD and PD polyplexes were observed (Fig. 5), indicating that the release of the polyplexes is governed by the dissolution rate of the hydrogel. Hydrogels can be physically cross-linked by noncovalent interactions or chemically cross-linked by covalent bond formation, or *via* a combination of both. In this study, the thermosensitive physical cross-linking causes the polyplex release to be dependent on dissolution of the hydrogel matrix and not on degradation of the chemical cross-links, which could offer an alternative strategy to tune the release kinetics.

It is important to note that the siRNA quantification measurements were performed after the addition of heparin to



dissociate the siRNA from the cationic polymers enabling intercalating of the RiboGreen reagent. This means that the detection does not discriminate between siRNA released in the form of polyplexes or free siRNA. Moreover, analyzing the release medium with dynamic light scattering does not give

insight whether polyplexes were released since this technique detects both polyplexes and nanoparticulate fragments of the hydrogel matrix. Therefore, FCS was used to evaluate whether in the release samples free siRNA was present or siRNA in the form of polyplexes. Since only the fluorescent signal of Alexa




Fig. 6 Characteristics of NPD and PD polyplexes (N/P 5) released from the thermosensitive hydrogel determined by fluorescence correlation spectroscopy (FCS) at 37 °C in HBS buffer (20 mM HEPES, 150 mM NaCl, pH 7.4). (A & B) Diffusion coefficient and size, respectively, of free Alexa 647 siRNA and freshly prepared polyplexes compared with polyplexes released after 8 and 72 hours from the hydrogel. (C & D) Diffusion coefficient and size, respectively, of Alexa 647 siRNA polyplexes released after 8 h with and without the addition of heparin. Free Alexa 647 siRNA was included as control. Measurements were performed at 37 °C and the values are given as the mean \pm SD ($n = 3$).




Fig. 7 (A) Agarose gel retardation assay of luciferase siRNA (siRNA-luc) released from the thermosensitive hydrogel when loaded in its free form, or as NPD and PD polyplexes (N/P 5). (B) In parallel, heparin was added to destabilize the polyplexes and release siRNA from the cationic polymers.



647 labeled siRNA was tracked, the presence of other particles derived from degradation of the hydrogel did not influence the measurement. The diffusion coefficient of free siRNA in buffer was slightly higher than that of free siRNA in release medium ($181 \pm 7 \mu\text{m}^2 \text{s}^{-1}$ and $154 \pm 17 \mu\text{m}^2 \text{s}^{-1}$, respectively), indicating only a minor effect of the NPN polymers on the viscosity of the release medium (Fig. 6A). More importantly, FCS measurements showed that the diffusion coefficients of NPD and PD polyplexes released after 8 hours were comparable to those before loading in the thermosensitive hydrogel (Fig. 6A), demonstrating that intact polyplexes were released from the thermosensitive hydrogel. The released polyplexes were similar in size as the ones before encapsulation (Fig. 6B). Even after

72 hours, the diffusion coefficient, and correspondingly the size, of the released NPD polyplexes were similar to freshly prepared polyplexes. For the PD polyplexes, the diffusion coefficient after 72 hours was slightly decreased, which also translated into larger particles (Fig. 6B). This might be explained by aggregation of the released polyplexes over time in the release medium. To confirm that indeed polyplexes were released, the strongly negatively charged heparin biopolymer was added to the release medium (at 8 hours) and the resulting samples were analyzed by FCS (Fig. 6C and D). For both type of polyplexes (NPD and PD polyplexes), the addition of this biopolymer resulted in an increase in diffusion coefficient from $\sim 38 \mu\text{m}^2 \text{s}^{-1}$ to $\sim 165 \mu\text{m}^2 \text{s}^{-1}$ (Fig. 6C). The larger diffusion




Fig. 8 *In vitro* transfection activity and cytotoxicity of freshly prepared and released NPD and PD polyplexes (N/P 5) on FaDu-luc cells. Cells were transfected for 6 h at 37 °C with luciferase siRNA (siRNA-luc) in its free form or formulated as polyplexes with a final siRNA concentration of 100 or 500 nM in serum supplemented culture medium. As a positive control, Lipofectamine and PEI, 25 kDa (N/P 6) were included and prepared freshly on the day of the experiment. As a negative control, non-coding siRNA (siRNA-nc) was included for all samples. Luciferase gene expression was determined by a luciferase reporter assay and plotted relative to untreated cells (A). Cell viability was determined by alamarBlue assay after incubation with the different formulations (B). The values are given as the mean \pm SD ($n = 3$).



coefficient correlates perfectly with the value for free siRNA, demonstrating destabilization of the polyplexes after addition of heparin. To further support the finding that intact polyplexes were released, agarose gel assay was performed which showed the absence of free siRNA (Fig. 7). Again, the addition of heparin to the release medium resulted in dissociation of the polyplexes, demonstrating also the reversibility of the complexation. As expected, free siRNA was detected in the release medium when incorporated into the hydrogel without the presence of cationic polymers (Fig. 7).

3.5. *In vitro* transfection activity of polyplexes

The transfection efficiency and cytotoxicity of polyplexes based on NPD and PD were evaluated in the presence of serum using FaDu-luc cells (Fig. 8). For the freshly prepared NPD and PD polyplexes, increasing the dose from 100 to 500 nM siRNA resulted in a lower luciferase expression and thus increased silencing (Fig. 8A). This increase in polyplex dose was associated with a slight drop in cell viability, which can be explained by the higher concentration of the cationic polymer to which the cells were exposed (Fig. 8B). It has been reported in many papers that cationic polymers adversely affect the viability of living cells.^{51,52} Furthermore, comparison of the silencing effects between luciferase siRNA (Fig. 8A, closed bars) and the non-coding siRNA (Fig. 8A, open bars) supports that the observed reduced luminescence observed upon incubation of the cells with the polyplex formulations was because of specific silencing of the luciferase gene and not related to their cytotoxicity. The commercially available transfection reagent Lipofectamine was included as control, and resulted in ~30% knockdown of the luciferase gene. This observed silencing effect of Lipofectamine is lower compared to the ~80% luciferase silencing as reported before.^{43,53} This however can be explained by differences in experimental conditions as in this study transfections were performed in full medium supplemented with FBS compared to serum-free conditions in other studies. Polyplexes prepared with l-PEI (25 kDa) performed in a similar way as the NPD and PD polyplexes with the same siRNA dose. Incubation of the cells with siRNA in its free form did not result in any luciferase gene silencing, which confirms the requirement of a delivery system for these molecules. The ability to induce siRNA-mediated gene silencing for polyplexes after being released at different time points from the hydrogel (Fig. 5 and Fig. S10†) was examined. Cells incubated with the supernatant from the hydrogels containing polyplexes showed a decrease in luciferase signal for all release samples tested (8, 24, 48 and 72 hours) with a gene knockdown ranging between 30–70% (Fig. 8A). These results further support the finding that intact polyplexes were released from the hydrogel, since siRNA released in its free form from the hydrogel was not able to induce silencing of luciferase (Fig. 8A). Additionally, limited cytotoxicity was observed for all released formulations (Fig. 8B). Similar to the freshly prepared polyplexes, increasing the polyplex dose from 100 to 500 nM siRNA resulted in an increased luciferase silencing with mild cytotoxicity (Fig. 8A and B). No significant differences in gene

silencing were observed between the NPD and PD polyplexes, however, PD polyplexes (100 nM) were slightly cytotoxic whereas NPD polyplexes were not (~86% and ~100% cell viability respectively). Similar results were reported before for pDNA polyplexes, where NPD polyplexes showed a better cytocompatibility than PD polyplexes with similar efficiencies of delivering its cargo into HeLa cells.²⁴ Together, these data show that the released siRNA polyplexes are able to enter cells and induce gene silencing.

4. Conclusion

This study shows the feasibility of an injectable thermosensitive hydrogel to promote local and sustained delivery of siRNA. Both the NPD and PD polymers formed small nanosized polyplexes (10–20 nm) with siRNA when prepared at a N/P ratio of 5 or higher which were stable under physiological conditions. Formulating siRNA into polyplexes using either the NPD or PD polymer before loading into the thermosensitive hydrogel resulted in a more controlled and sustained release compared to free siRNA. The results presented here also demonstrate that intact polyplexes were released suggesting that the hydrogel material does not compromise the polyplex stability. Importantly, transfection experiments demonstrated that the released polyplexes were still active by promoting the cellular uptake and luciferase gene silencing in FaDu cells. This polyplex-hydrogel delivery approach could potentially be used to deliver siRNA for various applications, such as the treatment of tumors, where an injectable hydrogel is valuable for localized retention of the nucleic acid cargo.

Conflicts of interest


There are no conflicts to declare.

Acknowledgements

The Netherlands Organization for Scientific Research (NWO/VIDI 13457 and NWO/Aspasia 015.009.038) is acknowledged for funding. The authors thank Cristina Casadidio for her contribution to this project.

References

- 1 A. Fire, S. Q. Xu, M. K. Montgomery, S. A. Kostas, S. E. Driver and C. C. Mello, Potent and specific genetic interference by double-stranded RNA in *Caenorhabditis elegans*, *Nature*, 1998, **391**(6669), 806–811.
- 2 S. M. Hoy, Patisiran: First Global Approval, *Drugs*, 2018, **78**(15), 1625–1631.
- 3 A. Akinc, M. A. Maier, M. Manoharan, K. Fitzgerald, M. Jayaraman, S. Barros, S. Ansell, X. Du, M. J. Hope, T. D. Madden, B. L. Mui, S. C. Semple, Y. K. Tam,



- M. Ciufolini, D. Witzigmann, J. A. Kulkarni, R. van der Meel and P. R. Cullis, The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs, *Nat. Nanotechnol.*, 2019, **14**(12), 1084–1087.
- 4 C. F. Bennett and E. E. Swayze, RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform, *Annu. Rev. Pharmacol. Toxicol.*, 2010, **50**, 259–293.
 - 5 K. A. Whitehead, J. E. Dahlman, R. S. Langer and D. G. Anderson, Silencing or stimulation? siRNA delivery and the immune system, *Annu. Rev. Chem. Biomol. Eng.*, 2011, **2**, 77–96.
 - 6 E. Wagner, Biomaterials in RNAi therapeutics: quo vadis?, *Biomater. Sci.*, 2013, **1**(8), 804–809.
 - 7 H. Yin, R. L. Kanasty, A. A. Eltoukhy, A. J. Vegas, J. R. Dorkin and D. G. Anderson, Non-viral vectors for gene-based therapy, *Nat. Rev. Genet.*, 2014, **15**, 541.
 - 8 R. Kanasty, J. R. Dorkin, A. Vegas and D. Anderson, Delivery materials for siRNA therapeutics, *Nat. Mater.*, 2013, **12**(11), 967–977.
 - 9 S. Agarwal, Y. Zhang, S. Maji and A. Greiner, PDMAEMA based gene delivery materials, *Mater. Today*, 2012, **15**(9), 388–393.
 - 10 E. Wagner, Polymers for nucleic acid transfer—an overview, *Adv. Genet.*, 2014, **88**, 231–261.
 - 11 U. Lachelt and E. Wagner, Nucleic Acid Therapeutics Using Polyplexes: A Journey of 50 Years (and Beyond), *Chem. Rev.*, 2015, **115**(19), 11043–11078.
 - 12 V. J. Venditto and F. C. Szoka Jr., Cancer nanomedicines: so many papers and so few drugs!, *Adv. Drug Delivery Rev.*, 2013, **65**(1), 80–88.
 - 13 J. L. Au, B. Z. Yeung, M. G. Wientjes, Z. Lu and M. G. Wientjes, Delivery of cancer therapeutics to extracellular and intracellular targets: Determinants, barriers, challenges and opportunities, *Adv. Drug Delivery Rev.*, 2016, **97**, 280–301.
 - 14 M. D. Krebs, O. Jeon and E. Alsberg, Localized and Sustained Delivery of Silencing RNA from Macroscopic Biopolymer Hydrogels, *J. Am. Chem. Soc.*, 2009, **131**(26), 9204–9206.
 - 15 M. K. Nguyen, O. Jeon, M. D. Krebs, D. Schapira and E. Alsberg, Sustained localized presentation of RNA interfering molecules from in situ forming hydrogels to guide stem cell osteogenic differentiation, *Biomaterials*, 2014, **35**(24), 6278–6286.
 - 16 L. L. Wang, J. N. Sloand, A. C. Gaffey, C. M. Venkataraman, Z. C. Wang, A. Trubelja, D. A. Hammer, P. Atluri and J. A. Burdick, Injectable, Guest-Host Assembled Polyethylenimine Hydrogel for siRNA Delivery, *Biomacromolecules*, 2017, **18**(1), 77–86.
 - 17 L. A. L. Fliervoet, J. F. J. Engbersen, R. M. Schiffelers, W. E. Hennink and T. Vermonden, Polymers and hydrogels for local nucleic acid delivery, *J. Mater. Chem. B*, 2018, **6**(36), 5651–5670.
 - 18 L. L. Wang and J. A. Burdick, Engineered Hydrogels for Local and Sustained Delivery of RNA-Interference Therapies, *Adv. Healthcare Mater.*, 2017, **6**(1), 1601041.
 - 19 J. E. Mealy, C. B. Rodell and J. A. Burdick, Sustained Small Molecule Delivery from Injectable Hyaluronic Acid Hydrogels through Host-Guest Mediated Retention, *J. Mater. Chem. B*, 2015, **3**(40), 8010–8019.
 - 20 K. N. Minh and D. S. Lee, Injectable Biodegradable Hydrogels, *Macromol. Biosci.*, 2010, **10**(6), 563–579.
 - 21 M. Norouzi, B. Nazari and D. W. Miller, Injectable hydrogel-based drug delivery systems for local cancer therapy, *Drug Discovery Today*, 2016, **21**(11), 1835–1849.
 - 22 M. Najafi, E. Hebel, W. E. Hennink and T. Vermonden, Poly(N-isopropylacrylamide): Physicochemical Properties and Biomedical Applications, in *Temperature-Responsive Polymers: Chemistry, Properties, and Applications*, ed. V. V. Khutoryanskiy and T. K. Georgiou, John Wiley & Sons, 2018, pp. 3–34.
 - 23 H. G. Schild, Poly(N-isopropylacrylamide): experiment, theory and application, *Prog. Polym. Sci.*, 1992, **17**(2), 163–249.
 - 24 L. A. L. Fliervoet, C. F. van Nostrum, W. E. Hennink and T. Vermonden, Balancing hydrophobic and electrostatic interactions in thermosensitive polyplexes for nucleic acid delivery, *Multifunct. Mater.*, 2019, **2**(2), 024002.
 - 25 S. Keereweere, I. M. Mol, A. L. Vahrmeijer, P. B. Van Driel, R. J. Baatenburg de Jong, J. D. Kerrebijn and C. W. Lowik, Dual wavelength tumor targeting for detection of hypopharyngeal cancer using near-infrared optical imaging in an animal model, *Int. J. Cancer*, 2012, **131**(7), 1633–1640.
 - 26 L. A. L. Fliervoet, M. Najafi, M. Hembury and T. Vermonden, Heterofunctional Poly(ethylene glycol) (PEG) Macroinitiator Enabling Controlled Synthesis of ABC Triblock Copolymers, *Macromolecules*, 2017, **50**(21), 8390–8397.
 - 27 A. J. de Graaf, S. Azevedo Prospero dos II, E. H. Pieters, D. T. Rijkers, C. F. van Nostrum, T. Vermonden, R. J. Kok, W. E. Hennink and E. Mastrobattista, A micelle-shedding thermosensitive hydrogel as sustained release formulation, *J. Controlled Release*, 2012, **162**(3), 582–590.
 - 28 O. Soga, C. F. van Nostrum and W. E. Hennink, Poly(N-(2-hydroxypropyl) methacrylamide mono/di lactate): A new class of biodegradable polymers with tuneable thermosensitivity, *Biomacromolecules*, 2004, **5**(3), 818–821.
 - 29 D. Neradovic, W. L. J. Hinrichs, K.-v. d. Bosch, J. J. Hennink and W. E. Hennink, Poly(N-isopropylacrylamide) with hydrolyzable lactic acid ester side groups: a new type of thermosensitive polymer, *Macromol. Rapid Commun.*, 1999, **20**(11), 577–581.
 - 30 H. Zhang, S. C. De Smedt and K. Remaut, Fluorescence Correlation Spectroscopy to find the critical balance between extracellular association and intracellular dissociation of mRNA complexes, *Acta Biomater.*, 2018, **75**, 358–370.
 - 31 E. L. Elson and D. Magde, Fluorescence correlation spectroscopy. I. Conceptual basis and theory, *Biopolymers*, 1974, **13**(1), 1–27.
 - 32 K. Remaut, B. Lucas, K. Braeckmans, N. N. Sanders, S. C. De Smedt and J. Demeester, FRET-FCS as a tool to



- evaluate the stability of oligonucleotide drugs after intracellular delivery, *J. Controlled Release*, 2005, **103**(1), 259–271.
- 33 E. V. van Gaal, R. van Eijk, R. S. Oosting, R. J. Kok, W. E. Hennink, D. J. Crommelin and E. Mastrobattista, How to screen non-viral gene delivery systems in vitro?, *J. Controlled Release*, 2011, **154**(3), 218–232.
 - 34 Z. Wang, C. Tiruppathi, R. D. Minshall and A. B. Malik, Size and dynamics of caveolae studied using nanoparticles in living endothelial cells, *ACS Nano*, 2009, **3**(12), 4110–4116.
 - 35 S. Xiang, H. Tong, Q. Shi, J. C. Fernandes, T. Jin, K. Dai and X. Zhang, Uptake mechanisms of non-viral gene delivery, *J. Controlled Release*, 2012, **158**(3), 371–378.
 - 36 A. Schroeder, C. G. Levins, C. Cortez, R. Langer and D. G. Anderson, Lipid-based nanotherapeutics for siRNA delivery, *J. Intern. Med.*, 2010, **267**(1), 9–21.
 - 37 K. Raemdonck, K. Remaut, B. Lucas, N. N. Sanders, J. Demeester and S. C. De Smedt, In Situ Analysis of Single-Stranded and Duplex siRNA Integrity in Living Cells, *Biochemistry*, 2006, **45**(35), 10614–10623.
 - 38 C. E. Barnett, Some Applications of Wave-length Turbidimetry in the Infrared, *J. Phys. Chem.*, 1942, **46**(1), 69–75.
 - 39 S. Bhattacharjee, DLS and zeta potential – What they are and what they are not?, *J. Controlled Release*, 2016, **235**, 337–351.
 - 40 R. J. Christie, Y. Matsumoto, K. Miyata, T. Nomoto, S. Fukushima, K. Osada, J. Halnaut, F. Pittella, H. J. Kim, N. Nishiyama and K. Kataoka, Targeted polymeric micelles for siRNA treatment of experimental cancer by intravenous injection, *ACS Nano*, 2012, **6**(6), 5174–5189.
 - 41 S. Florinas, M. Liu, R. Fleming, L. Van Vlerken-Ysla, J. Ayriss, R. Gilbreth, N. Dimasi, C. Gao, H. Wu, Z.-Q. Xu, S. Chen, A. Dirisala, K. Kataoka, H. Cabral and R. J. Christie, A Nanoparticle Platform To Evaluate Bioconjugation and Receptor-Mediated Cell Uptake Using Cross-Linked Polyion Complex Micelles Bearing Antibody Fragments, *Biomacromolecules*, 2016, **17**(5), 1818–1833.
 - 42 K. Hayashi, H. Chaya, S. Fukushima, S. Watanabe, H. Takemoto, K. Osada, N. Nishiyama, K. Miyata and K. Kataoka, Influence of RNA Strand Rigidity on Polyion Complex Formation with Block Cationomers, *Macromol. Rapid Commun.*, 2016, **37**(6), 486–493.
 - 43 B. Lou, N. Beztsinna, G. Mountrichas, J. B. van den Dikkenberg, S. Pispas and W. E. Hennink, Small nanosized poly(vinyl benzyl trimethylammonium chloride) based polyplexes for siRNA delivery, *Int. J. Pharm.*, 2017, **525**(2), 388–396.
 - 44 M. Miteva, K. C. Kirkbride, K. V. Kilchrist, T. A. Werfel, H. Li, C. E. Nelson, M. K. Gupta, T. D. Giorgio and C. L. Duvall, Tuning PEGylation of mixed micelles to overcome intracellular and systemic siRNA delivery barriers, *Biomaterials*, 2015, **38**, 97–107.
 - 45 C. Dufès, W. N. Keith, A. Bilsland, I. Proutski, I. F. Uchegbu and A. G. Schätzlein, Synthetic Anticancer Gene Medicine Exploits Intrinsic Antitumor Activity of Cationic Vector to Cure Established Tumors, *Cancer Res.*, 2005, **65**(18), 8079–8084.
 - 46 H. J. Kim, H. Takemoto, Y. Yi, M. Zheng, Y. Maeda, H. Chaya, K. Hayashi, P. Mi, F. Pittella, R. J. Christie, K. Toh, Y. Matsumoto, N. Nishiyama, K. Miyata and K. Kataoka, Precise engineering of siRNA delivery vehicles to tumors using polyion complexes and gold nanoparticles, *ACS Nano*, 2014, **8**(9), 8979–8991.
 - 47 K. Remaut, B. Lucas, K. Raemdonck, K. Braeckmans, J. Demeester and S. C. De Smedt, Protection of Oligonucleotides against Enzymatic Degradation by Pegylated and Nonpegylated Branched Polyethyleneimine, *Biomacromolecules*, 2007, **8**(4), 1333–1340.
 - 48 Y. Liu, O. Samsonova, B. Sproat, O. Merkel and T. Kissel, Biophysical characterization of hyper-branched polyethyleneimine-graft- polycaprolactone-block-mono-methoxyl-poly (ethylene glycol) copolymers (hy-PEI-PCL-mPEG) for siRNA delivery, *J. Controlled Release*, 2011, **153**(3), 262–268.
 - 49 C. L. McCormick, B. S. Sumerlin, B. S. Lokitz and J. E. Stempka, RAFT-synthesized diblock and triblock copolymers: thermally-induced supramolecular assembly in aqueous media, *Soft Matter*, 2008, **4**(9), 1760–1773.
 - 50 A. N. Semenov, J. F. Joanny and A. R. Khokhlov, Associating polymers: Equilibrium and linear viscoelasticity, *Macromolecules*, 1995, **28**(4), 1066–1075.
 - 51 D. Fischer, Y. Li, B. Ahlemeyer, J. Krieglstein and T. Kissel, In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis, *Biomaterials*, 2003, **24**(7), 1121–1131.
 - 52 P. van de Wetering, J. Y. Cherng, H. Talsma and W. E. Hennink, Relation between transfection efficiency and cytotoxicity of poly(2-(dimethylamino)ethyl methacrylate)/plasmid complexes, *J. Controlled Release*, 1997, **49**(1), 59–69.
 - 53 E. E. Oude Blenke, J. van den Dikkenberg, B. van Kolck, A. Kros and E. Mastrobattista, Coiled coil interactions for the targeting of liposomes for nucleic acid delivery, *Nanoscale*, 2016, **8**(16), 8955–8965.

